<DOC>
	<DOC>NCT02023112</DOC>
	<brief_summary>This is a Phase 3, randomized, open-label, multicenter study, enrolling non-cirrhotic and cirrhotic subjects. The purpose of this study is to evaluate the efficacy and safety of ABT-450/r/ABT-267 co-administered with weight-based RBV for 12 or 16 weeks in adult chronic HCV genotype 2-infected treatment-na√Øve and interferon (IFN) treatment-experienced subjects with and without compensated cirrhosis.</brief_summary>
	<brief_title>Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT- 267 (ABT-450/r/ABT-267) in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus (HCV) Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<criteria>Chronic HCVinfection prior to study enrollment Screening laboratory result indicating HCV genotype 2 infection Subject has plasma HCV ribonucleic acid (RNA) level greater than 10,000 IU/mL at Screening Voluntarily sign an informed consent Coinfection of Hepatitis B Virus (HBV), human immunodeficiency virus (HIV) and any HCV genotype other than genotype 2 Prior therapy with direct acting antiviral agents for the treatment of HCV, including telaprevir, simeprevir and boceprevir Any cause of liver disease other than chronic HCVinfection, including but not limited to the following: hemochromatosis; alpha1 antitrypsin deficiency; Wilson's disease; autoimmune hepatitis; alcoholic liver disease; drugrelated liver disease Clinically significant laboratory abnormalities Uncontrolled clinically significant disease, disorder or medical illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Japanese</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Treatment naive</keyword>
	<keyword>Treatment experienced</keyword>
	<keyword>Genotype 2</keyword>
	<keyword>Ombitasvir</keyword>
	<keyword>Paritaprevir</keyword>
	<keyword>Ritonavir</keyword>
	<keyword>Ribavirin</keyword>
	<keyword>VIEKIRAX Combination Tablets</keyword>
</DOC>